Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

Background: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4, The cholesterol-lowering drug simvas tatin has an extensive first-pass metabolism, and it is partially metaboliz ed by CYP3A4, This study was conducted to investigate the effect of rifampi n on the pharmacokinetics of simvastatin, Methods: In a randomized cross-over study with two phases and a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampin (600 mg daily) or placebo. On day 6, a single 40-mg dose of simvastatin was administered orally, Plasma concentrations of simvastatin and its active m etabolite simvastatin acid were measured up to 12 hours with a sensitive li quid chromatography-ion spray tandem mass spectrometry method. Results: Rifampin decreased the total area under the plasma concentration-t ime curve of simvastatin and simvastatin acid by 87% (P < .001) and 93% (P < .001), respectively. Also the peak concentrations of both simvastatin and simvastatin acid were reduced greatly (by 90%) by rifampin (P < .001). On the other hand, rifampin had no significant effect on the elimination half- life of simvastatin or simvastatin acid, Conclusions: Rifampin greatly decreases the plasma concentrations of simvas tatin and simvastatin acid. Because the elimination half-life of simvastati n was not affected by rifampin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction. Concomitant use of potent inducers of CYP3A4 can lead to a considerably reduced cholesterol-lowering efficacy of simvastatin.